Carr B R, Rainey W E, Mason J I
J Clin Invest. 1985 Nov;76(5):1946-9. doi: 10.1172/JCI112192.
In previous investigations, we have found that the liver appears to be the major source of cholesterol in the human fetus, and, in particular, a principal source of circulating low density lipo-protein-cholesterol (LDL-C). LDL-C plasma levels are low in the normal fetus, most likely due to the rapid uptake and metabolism by the fetal adrenal as precursor for steroid hormone biosynthesis. In contrast, in the anencephalic fetus the adrenals are atrophic, the rate of estrogen and glucocorticoid production is low, and the levels of LDL-C in fetal plasma are high. The purpose of the present investigation was to determine the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the primary rate-limiting enzyme of cholesterol biosynthesis, in anencephalic liver and normal fetal liver. We found that the specific activity of HMG-CoA reductase in normal fetal liver microsomes was 0.428 +/- 0.054 nmol mevalonate formed times mg-1 protein X min-1 (mean +/- SE, n = 9). The rate of HMG-CoA reductase in anencephalic liver microsome preparations was 10-fold less (0.040 +/- 0.003) (mean +/- SE, n = 7) P less than 0.001. Furthermore, we detected HMG-CoA reductase (97,000-mol wt protein) in normal human fetal liver after SDS PAGE and immunoblotting by using a monoclonal antibody directed against HMG-CoA reductase. We were unable to detect any significant quantity of HMG-CoA reductase protein in anencephalic fetal liver, which indicates that low reductase activity was due to low amounts of enzyme protein rather than inactive enzyme. In summary, we conclude that the low levels of cholesterol synthesis observed in anencephalic fetal liver are probably due to both the high levels of LDL-C in fetal plasma as well as the presence of low circulating levels of estrogens and glucocorticoids and that these factors regulate cholesterol synthesis both in vivo and in vitro in fetal liver. This occurs most probably by the modulation of the amount of HMG-CoA reductase, a primary rate-limiting and regulatory enzyme of the cholesterol biosynthetic sequence.
在先前的研究中,我们发现肝脏似乎是人类胎儿胆固醇的主要来源,尤其是循环中低密度脂蛋白胆固醇(LDL-C)的主要来源。正常胎儿的LDL-C血浆水平较低,这很可能是由于胎儿肾上腺将其作为类固醇激素生物合成的前体快速摄取和代谢所致。相比之下,无脑儿胎儿的肾上腺萎缩,雌激素和糖皮质激素的产生速率较低,胎儿血浆中的LDL-C水平较高。本研究的目的是测定3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶(胆固醇生物合成的主要限速酶)在无脑儿肝脏和正常胎儿肝脏中的活性。我们发现,正常胎儿肝脏微粒体中HMG-CoA还原酶的比活性为0.428±0.054 nmol甲羟戊酸形成量×mg-1蛋白×min-1(平均值±标准误,n = 9)。无脑儿肝脏微粒体制剂中HMG-CoA还原酶的活性低10倍(为0.040±0.003)(平均值±标准误,n = 7),P < 0.001。此外,我们通过使用针对HMG-CoA还原酶的单克隆抗体进行SDS-PAGE和免疫印迹后,在正常人类胎儿肝脏中检测到了HMG-CoA还原酶(97,000道尔顿分子量的蛋白质)。我们在无脑儿胎儿肝脏中未能检测到任何显著量的HMG-CoA还原酶蛋白,这表明还原酶活性低是由于酶蛋白量低而非酶无活性所致。总之,我们得出结论,无脑儿胎儿肝脏中观察到的胆固醇合成水平低可能是由于胎儿血浆中LDL-C水平高以及雌激素和糖皮质激素循环水平低所致,并且这些因素在体内和体外均调节胎儿肝脏中的胆固醇合成。这很可能是通过调节HMG-CoA还原酶的量来实现的,HMG-CoA还原酶是胆固醇生物合成序列中的主要限速和调节酶。